380 related articles for article (PubMed ID: 29754585)
21. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
Seligson ND; Knepper TC; Ragg S; Walko CM
Clin Pharmacol Ther; 2021 Feb; 109(2):334-342. PubMed ID: 32535906
[TBL] [Abstract][Full Text] [Related]
22. Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence.
Passaro A; Stenzinger A; Peters S
Cancer Cell; 2020 Nov; 38(5):624-625. PubMed ID: 33171127
[TBL] [Abstract][Full Text] [Related]
23. First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.
Lemery S; Keegan P; Pazdur R
N Engl J Med; 2017 Oct; 377(15):1409-1412. PubMed ID: 29020592
[No Abstract] [Full Text] [Related]
24.
van der Veen EL; Giesen D; Pot-de Jong L; Jorritsma-Smit A; De Vries EGE; Lub-de Hooge MN
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020241
[TBL] [Abstract][Full Text] [Related]
25. The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine.
Riley JM; Cross AW; Paulos CM; Rubinstein MP; Wrangle J; Camp ER
Cancer; 2018 Apr; 124(8):1650-1659. PubMed ID: 29315503
[TBL] [Abstract][Full Text] [Related]
26. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
[TBL] [Abstract][Full Text] [Related]
27. Advances in theranostic biomarkers for tumor immunotherapy.
Bellesoeur A; Torossian N; Amigorena S; Romano E
Curr Opin Chem Biol; 2020 Jun; 56():79-90. PubMed ID: 32217357
[TBL] [Abstract][Full Text] [Related]
28. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
Pai-Scherf L; Blumenthal GM; Li H; Subramaniam S; Mishra-Kalyani PS; He K; Zhao H; Yu J; Paciga M; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2017 Nov; 22(11):1392-1399. PubMed ID: 28835513
[TBL] [Abstract][Full Text] [Related]
29. Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy.
Chang L; Chang M; Chang HM; Chang F
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):e15-e21. PubMed ID: 28877075
[TBL] [Abstract][Full Text] [Related]
30. Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair-Deficient Colorectal Cancer.
Gurjao C; Liu D; Hofree M; AlDubayan SH; Wakiro I; Su MJ; Felt K; Gjini E; Brais LK; Rotem A; Rosenthal MH; Rozenblatt-Rosen O; Rodig S; Ng K; Van Allen EM; Corsello SM; Ogino S; Regev A; Nowak JA; Giannakis M
Cancer Immunol Res; 2019 Aug; 7(8):1230-1236. PubMed ID: 31217164
[TBL] [Abstract][Full Text] [Related]
31. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.
Mehrvarz Sarshekeh A; Overman MJ; Kopetz S
Future Oncol; 2018 Aug; 14(18):1869-1874. PubMed ID: 29473436
[TBL] [Abstract][Full Text] [Related]
32. Upper gastrointestinal malignancies in 2017: current perspectives and future approaches.
Solomon BL; Garrido-Laguna I
Future Oncol; 2018 Apr; 14(10):947-962. PubMed ID: 29542354
[TBL] [Abstract][Full Text] [Related]
33. In brief: Pembrolizumab (Keytruda) for cancers with biomarkers.
Med Lett Drugs Ther; 2018 Jan; 60(1537):e8. PubMed ID: 29294466
[No Abstract] [Full Text] [Related]
34. Making precision oncology the standard of care.
The Lancet Oncology
Lancet Oncol; 2017 Jul; 18(7):835. PubMed ID: 28677559
[No Abstract] [Full Text] [Related]
35. DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers.
Ruiz-Bañobre J; Goel A
Gastroenterology; 2019 Mar; 156(4):890-903. PubMed ID: 30578781
[TBL] [Abstract][Full Text] [Related]
36. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
[TBL] [Abstract][Full Text] [Related]
37. Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline
Dizon DS; Dias-Santagata D; Bregar A; Sullivan L; Filipi J; DiTavi E; Miller L; Ellisen L; Birrer M; DelCarmen M
Oncologist; 2018 Jun; 23(6):650-653. PubMed ID: 29472312
[TBL] [Abstract][Full Text] [Related]
38. Pembrolizumab for the treatment of gastric cancer.
Kamath SD; Kalyan A; Benson AB
Expert Rev Anticancer Ther; 2018 Dec; 18(12):1177-1187. PubMed ID: 30280940
[TBL] [Abstract][Full Text] [Related]
39. New Indication for Cancer Drug Based on Biomarkers.
Aschenbrenner DS
Am J Nurs; 2017 Sep; 117(9):22. PubMed ID: 28837483
[No Abstract] [Full Text] [Related]
40. Tissue-Agnostic Drug Development: A New Path to Drug Approval.
Thein KZ; Lemery SJ; Kummar S
Cancer Discov; 2021 Sep; 11(9):2139-2144. PubMed ID: 34479971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
